Rheumatological Pharmacology

Pharmacology · Clinical Bases

How it begins

Guía de referencia experta: mecanismos de acción, farmacocinética, indicaciones, monitoreo de seguridad e interacciones de los fármacos modificadores de enfermedad, biológicos, inhibidores de JAK, hipouricemiantes y farmacología ósea en el contexto de las enfermedades reumáticas.

What it covers

1. · Drugs in Rheumatic Diseases
2. Introduction: Classification and Therapeutic Strategy
3. · 1.1 General Classification of Rheumatological Drugs
4. · 1.2 Immunological Basis of Therapeutic Targets
5. NSAIDs and Specific Analgesics
6. · 2.1 Classic NSAIDs (Non-Selective COX-1/COX-2)
7. · 2.2 Selective COX-2 Inhibitors (Coxibs)
8. · 2.3 Colchicine: Mechanism, Uses and Safety
9. Glucocorticoids in Rheumatology
10. · 3.1 Mechanism of Action of Glucocorticoids
11. · 3.2 Glucocorticoid Toxicity — Systematic Analysis
12. csDMARDs: Conventional Synthetic DMARDs
13. · 4.1 Methotrexate (MTX)
14. · 4.2 Hydroxychloroquine (HCQ)
15. · 4.3 Sulfasalazine (SSZ)
16. · 4.4 Leflunomide
17. · 4.5 Azathioprine (AZA)
18. · 4.6 Mycophenolate Mofetil (MMF) and Mycophenolic Acid (MPA)
19. · 4.7 Cyclophosphamide (CYC)
20. · 4.8 Cyclosporin A and Tacrolimus
21. Recap: Part I
22. bDMARDs: Biological Drugs
23. · 5.1 TNF-α inhibitors (Anti-TNF)
24. · 5.2 IL-6 Inhibitors / IL-6 Receptor
25. · 5.3 IL-17 and IL-23 inhibitors
26. · 5.4 IL-1 inhibitors
27. · 5.5 Rituximab — Anti-CD20
28. · 5.6 Abatacept — T Costimulation Modulation
29. · 5.7 Belimumab and Anifrolumab — SLE specific
30. · 5.8 Ustekinumab — Anti-IL-12/23
31. tsDMARDs: JAK Inhibitors
32. · 6.1 The JAK/STAT Pathway: Molecular Pharmacology
33. · 6.2 Comparison of JAK Approved Inhibitors
34. · 6.3 Safety of JAK Inhibitors — The ORAL Surveillance Study and its Implications
35. Pharmacology of Gout and Hyperuricemia
36. · 7.1 Allopurinol and Febuxostat — Xanthine Oxidase Inhibitors
37. · 7.2 Uricosurics and Pegloticase
38. · 7.3 Treatment of Acute Gout Attack
39. Pharmacology of Osteoporosis
40. · 8.1 Bisphosphonates — First Line Antiresorptives
41. · 8.2 Denosumab — Anti-RANKL
42. · 8.3 Bone Anabolic Drugs
43. Pre-Treatment Screening and Monitoring
44. · 9.1 Latent Tuberculosis (TBL) — Mandatory Protocol Before Biologics and JAKibs
45. Infections in the Immunosuppressed Rheumatological Patient
46. Rheumatological Drugs in Pregnancy and Breastfeeding
47. Relevant Drug Interactions
48. Global Monitoring Table — Quick Reference